| 104773-7 | NCBI Sample Accession Number in Specimen | MICRO |
| 104774-5 | Salmonella sp antigenic formula in Isolate (sequencing) | MICRO |
| 104775-2 | Medication total daily effective dose Medication | MEDS |
| 104776-0 | Parainfluenza virus 2 RNA in Specimen (qualitative, molecular genetics method) | MICRO |
| 104777-8 | Medication safety override reason | MEDS |
| 104778-6 | Medication maximum dose Medication | MEDS |
| 104779-4 | Schistocytes (qualitative) | HEM/BC |
| 10478-6 | Eosinophil major basic protein Ag (Tissue, qualitative, immune stain) | PATH |
| 104780-2 | Neisseria gonorrhoeae rRNA in Specimen (qualitative, molecular genetics method) | MICRO |
| 104781-0 | HIV 1 RNA (molecular genetics method) | MICRO |
| 104782-8 | Order start date | CLIN |
| 104783-6 | Human papilloma virus E6+E7 mRNA in Cervix (qualitative, molecular genetics method) | MICRO |
| 104784-4 | Medication start criterion Narrative | MEDS |
| 104785-1 | Hepatitis B virus core IgM Ab | MICRO |
| 104786-9 | Alpha 1 globulin | CHEM |
| 104787-7 | Medication duration completed Reporting Period Medication Narrative | MEDS |
| 104788-5 | Gardnerella vaginalis rRNA in Genital specimen (qualitative, molecular genetics method) | MICRO |
| 104789-3 | Toxic granules (qualitative) | HEM/BC |
| 10479-4 | CD227 Ag (Tissue, qualitative, immune stain) | CELLMARK |
| 104790-1 | Medication maximum dose allowed period Medication | MEDS |
| 104791-9 | Medication dispense expiry date Medication | MEDS |
| 104792-7 | Medication administration specific directions Narrative | MEDS |
| 104793-5 | Therapeutic direction duration | CLIN |
| 104794-3 | Human coronavirus HKU1 RNA in Specimen (qualitative, molecular genetics method) | MICRO |
| 104795-0 | Sickle cells (qualitative) | HEM/BC |
| 104796-8 | Medication additional instruction Medication Narrative | MEDS |
| 104797-6 | Base excess standard (Arterial Blood) | CHEM |
| 104798-4 | Basophilic stippling (qualitative) | HEM/BC |
| 104799-2 | Alpha 2 globulin | CHEM |
| 1048-8 | H NOS Ag on Red Blood Cells from Blood product unit (qualitative) | BLDBK |
| 10480-2 | Estrogen+Progesterone receptor Ag (Tissue, qualitative, immune stain) | PATH |
| 104800-8 | Spherocytes (qualitative) | HEM/BC |
| 104801-6 | Beta globulin | CHEM |
| 104802-4 | Variant lymphocytes (qualitative) | HEM/BC |
| 104803-2 | Therapeutic intent Narrative | MEDS |
| 104804-0 | Medication substitution criterion Medication Narrative | MEDS |
| 104805-7 | Creatinine renal clearance predicted | CHEM |
| 104806-5 | Trichomonas vaginalis DNA in Specimen (qualitative, molecular genetics method) | MICRO |
| 104807-3 | Medication cessation date time | MEDS |
| 104808-1 | Medication dispense priority Medication Narrative | MEDS |
| 104809-9 | Medication dosage justification Medication Narrative | MEDS |
| 10481-0 | Follitropin.alpha subunit Ag (Tissue, qualitative, immune stain) | PATH |
| 104810-7 | Medication total daily amount 24 hour Medication | MEDS |
| 104811-5 | Epstein Barr virus DNA in Specimen (molecular genetics method) | MICRO |
| 104812-3 | Base excess in Venous cord blood | CHEM |
| 104813-1 | Gamma globulin | CHEM |
| 104814-9 | Lactate dehydrogenase 1/Lactate dehydrogenase.total (Urine) | CHEM |
| 104815-6 | Chlamydia trachomatis DNA in Specimen (qualitative, molecular genetics method) | MICRO |
| 104816-4 | Beta hydroxybutyrate (Blood) | CHEM |
| 104817-2 | Medication administration method Medication | MEDS |